NeuroSense Therapeutics
randomized prospective double blind placebo controlled study phase design placebo controlled road | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
26 of 33
Similar slides by NeuroSense Therapeutics
See diffirences between slides (animation)
Investor Presentation
December 2023
randomized prospective double blind placebo controlled study phase design placebo controlled road | NeuroSense Therapeutics
Investor Presentation
June 2023
phase trial design | NeuroSense Therapeutics
Related slides by other companies
Xeris Biopharma
Investor Presentation
October 2022
phase study design | Xeris Biopharma
Aeglea BioTherapeutics
Results
December 2021
peace phase study of in patients with | Aeglea BioTherapeutics
Equillium
Investor Presentation
August 2023
phase first in human study of single ascending dose multiple ascending dose proof of concept study in celiac disease patients | Equillium
Equillium
Investor Presentation
November 2023
phase first in human study of single ascending dose multiple ascending dose proof of concept study in celiac disease patients | Equillium
Other recent decks by NeuroSense Therapeutics
See all presentations (3 decks)
Investor Presentation
December 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io